ANAHEIM, CA–(Marketwire – September 22, 2010) – Leading wound care experts will present a Poster highlighting results from a multicenter randomized controlled trial (RCT) comparing negative pressure wound therapy (NPWT) between the SNaP® Wound Care System from Spiracur, Inc., of Sunnyvale, Calif., and the Wound V.A.C.® Therapy System from Kinetic Concepts, Inc. of San Antonio, Texas, for the treatment of chronic lower extremity ulcers. The Poster will be presented at the Fall 2010 Symposium on Advanced Wound Care (SAWC) in Anaheim, Calif.

Background:  The SNaP Wound Care System is an ultraportable and disposable NPWT device that was approved by the U.S. Food & Drug Administration (FDA) in August 2009 in a new technology category the FDA defined as “non-powered” NPWT devices. It is currently available for purchase in the U.S. The new system produces the same level of negative pressure as competitive technologies; however, it requires no electric or battery power making treatment completely silent. In addition, the therapy system weighs less than three ounces, enabling patients to wear the device under clothing and resume daily activity during the course of treatment.

About Spiracur, Inc.
Spiracur, Inc. is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford Biodesign Innovation program in 2007. Its first product, the SNaP Wound Care System, grew out of the notion that current negative pressure wound therapies were too cumbersome for patients and clinicians. Spiracur strives to develop products that are truly patient-centric. For more information, please visit http://www.spiracur.com.

SNaP and Spiracur are registered trademarks of Spiracur, Inc.

CENTERVILLE, MA–(Marketwire – September 22, 2010) –  UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) announced today that in response to recent outbreaks of drug resistant superbugs such as NDM-1, and persistent occurrences of highly contagious strains of bacteria such as MRSA, the Company is implementing a national campaign to inform the public how its ViraTech UV-400 indoor air purifier significantly helps reduce exposure risks.

Dr. Wladyslaw Jan Kowalski, PE, Phd, a world leading expert on the bacteria killing efficacy of ultraviolet light, recently commented on the UV-400: “Ultraviolet germicidal irradiation (UVGI) destroys bacteria by damaging the nucleic acids and thereby preventing reproduction. Multidrug-resistant microbes (superbugs) may have resistance to antibiotics but they remain as susceptible to ultraviolet radiation as any normal bacteria variant. The number of multidrug resistant microbes has been increasing, apparently due to overuse of antibiotics and other factors, and is expected to pose a serious challenge to health care facilities in the future as treatment options diminish.”

Dr. Kowalski further added, “The ViraTech UV-400 model air cleaner has a demonstrated ability to disinfect air and inactivate a wide range of bacterial pathogens including Staphylococcus aureus (MRSA), Pseudomonas, and Klebsiella as has been conclusively demonstrated in independent laboratory tests. The UV-400 produces a germicidal UV exposure dose of 41 J/m², as independently verified by biodosimetric testing, which is sufficient to reduce pathogenic bacterial populations by at least 99%. This disinfection rate will apply regardless of the multidrug resistance of bacteria such as those that may contain the NDM-1 enzyme (the superbug gene). The ViraTech UV-400 unit provides a viable option for health care facilities struggling to cope with the growing problem of multidrug resistant organisms and this technology can serve as an adjunct to existing infection management procedures and disinfection protocols wherever the potential exists for microorganisms to spread by the airborne route.”

“Our Company receives reports from around the world on an almost daily basis about the growing problems connected with the spread of these increasingly drug resistant bacterial strains,” said Jack Lennon, President of UV Flu Technologies. “Antibiotics have become so pervasive in today’s medical therapies, that not only are they becoming less effective, but their overuse is increasingly being considered as part of the problem. Drug-resistant superbugs have now been found in 20 states, as well as worldwide, and when they hit the critically ill, they can be fatal 30-60% of the time. In one recent incident at an infant ward at the University College Hospital in London, 15 babies in the unit were found to be carrying several types of bacteria, including 13 who had bacterial superbugs resistant to treatment. Of four babies seriously infected, one survived.”

“So that the public can participate in actions to help reduce the spread of these strains, the Company has committed to advertising, including television and other media in order to educate consumers and to offer help where needed,” said Mr. Lennon. “We are looking to develop a plan to offer our UV-400 indoor air quality units either free or at significantly discounted costs to those schools and hospitals that suffer from serious outbreaks. We hope to partner with institutions which are genuinely interested in working with us in order to develop an action plan for their facilities. For those with respiratory problems or weakened immune systems, hospital or institution acquired bacterial infections can prove deadly. We believe our product delivers an immediate, effective and proven ability to kill at least 99% of airborne bacteria thereby reducing the risk of infection.”

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available without a prescription. 

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO

Click here to see all recent news from this company

AMSTERDAM, THE NETHERLANDS–(Marketwire – September 22, 2010) –  Information Builders, the independent leader in operational business intelligence (BI) systems, today announced that The Dutch Cancer Institute — Antoni van Leeuwenhoek Hospital (NKI-AVL) has implemented the WebFOCUS BI platform. Using Information Builders’ technology, the NKI-AVL is able to optimize internal processes and to reduce operational costs.

The NKI-AVL consists of a center for scientific cancer research, the Dutch Cancer Institute, and an oncologic hospital, the Antoni van Leeuwenhoek Hospital. The NKI-AVL collaborates with national and foreign hospitals and laboratories and fulfills a leading role with regard to new developments in the fight against cancer.

This year, the NKI-AVL started an expansion process with the ultimate goal of growing up to 45 percent within the next ten years. To facilitate its growth, the institute needed to increase efficient operational processes and decrease operational costs. To measure the efficiency targets in the expansion plan and to gain better insight into costs, the NKI-AVL decided to select a suitable reporting and analysis environment. 

After a comprehensive and detailed tendering process, based on a pilot project, the NKI-AVL selected Information Builders’ WebFOCUS. The BI platform will first be deployed to gain insights in the production and financial information from the SAP and ChipSoft systems. In the second phase, all the research data from the NKI-AVL will be extracted as well.

“WebFOCUS is a multilateral platform. Many other BI solutions mainly focus on finance, while with this platform we are perfectly able to extract and share our healthcare and research information as well,” says Michel Glintmeijer, Head of Information and Financial Services at the NKI-AVL. “We used to connect SAP and ChipSoft through Excel, now we can rely on one reporting tool for all systems. With this solution, we gain much more insight in a much shorter time frame. Ultimately, we will set up a data warehouse and will start with forecasting based on scenario analytics.”

“We are very pleased that the NKI-AVL has selected Information Builders as a strategic partner to implement process optimization and aid with organizational growth,” says Dave Kemme, sales manager, Benelux, at Information Builders. “WebFOCUS offers the NKI-AVL the opportunity to present all relevant information company wide to the management and employees. Furthermore, the organization can start working with scenario planning based on analysis. An extra advantage is that the NKI-AVL will be able to measure governmental performance indicators that are automatically included in WebFOCUS.”

About NKI-AVL
The Dutch Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL) accommodates approximately 550 scientists and scientific support personnel, 53 medical specialists, 180 beds, an outpatient clinic that receives 24,000 new patients each year, 5 operating theaters, and 9 irradiation units. It is the only dedicated cancer center in The Netherlands and maintains an important role as a national and international center of scientific and clinical expertise, development, and training. The three major areas of research are fundamental, clinical, and translational cancer research.

From its first inception, the NKI-AVL is convinced close collaboration between scientists and clinicians is essential to fighting cancer. Having a laboratory and hospital under one roof in a single independent organization with an open and collaborative atmosphere has led to many important discoveries and improved therapies.

About Information Builders
Information Builders’ award-winning combination of business intelligence (BI) and enterprise integration software has been providing innovative solutions to more than 12,000 customers for the past 30 years. WebFOCUS is the world’s most widely utilized business intelligence platform. It provides the security, scalability, and flexibility needed at every level of global extended enterprises. Its simplicity helps create executive, analytical, and operational applications that reach dozens to millions of users. Information Builders’ iWay Software suite provides state of the art, multi-purpose, pre-built integration components that address all SOA, application, data and information management requirements. Its integration adapters have been adopted by the leading software platform providers. Information Builders also offers solutions in the performance management, business activity monitoring, and enterprise search markets. The company’s comprehensive enterprise product offerings give Information Builders’ customers the ability to grow and innovate according to their needs.

Information Builders’ customers include most of the Fortune 100 and U.S. federal government agencies. Headquartered in New York City with 90 offices worldwide, the company employs 1,450 people and has more than 350 business partners. More information is available at informationbuilders.com.

Click here to see all recent news from this company

BOCA RATON, FL–(Marketwire – September 22, 2010) –  Vicor Technologies, Inc. (OTCBB: VCRT), today announced that CEO David Fater’s interview by The Wall Street Transcript for its September 20, 2010 Medical Devices Report is now available for download at the company’s website: www.vicortech.com. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

“We are gratified to have been given the opportunity to discuss Vicor’s product commercialization status in The Wall Street Transcript‘s Medical Devices Report. This is an exciting time for Vicor and we’re eager to share our progress with those following the evolving medical device industry,” stated Mr. Fater.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i^® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Institute for Surgical Research of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-16

Click here to see all recent news from this company

ST. LOUIS, MO–(Marketwire – September 22, 2010) –  Life Uniform, the leader for today’s healthcare fashion trends, will be launching a new and exclusive collection of Laura Ashley medical apparel on September 30^th, 2010 nationwide. Building on a tradition of providing fashion-forward styles, innovative products, the most popular brands, and exclusive styles for 45 years, Life Uniform will introduce their latest fashion in medical scrubs under the Laura Ashley name. Laura Ashley has granted exclusive licensing rights to Life Uniform to design, manufacture, and sell medical scrub tops and pants through their retail outlets and online.

“The Life Uniform and Laura Ashley collaboration is a great opportunity to offer consumers fashionable, affordable, and premium quality medical apparel that encompasses the essence of two great brands,” says Life Uniform’s President and CEO Jim Rudd. “We are excited to bring another fashion choice to our customers who look for distinctive designs that reflect their own individual style.”

“The field of healthcare is dominated by women who are looking for styles and colors that reflect their individual personalities,” says Laura Ashley Vice President of Licensing Penne Cairoli. “We believe the classic yet contemporary style of Laura Ashley will resonate exceptionally well with so many of the dedicated professionals throughout this field.”

The new Laura Ashley medical scrubs can be found in all Life stores and online beginning September 30^th, 2010 with a special in-store celebration on that day to include refreshments and drawings.

About Life Uniform
Life Uniform, headquartered in St. Louis, MO, has been providing fashionable medical uniforms and accessories since 1965. With nearly 200 stores nationwide, on premise hospital stores and a sophisticated online store, Life Uniform is a one-stop shopping destination for all healthcare apparel, medical uniforms, scrubs, nurses shoes, lab coats, hosiery and healthcare accessory needs. Life Uniform represents top brands including Cherokee, Dickies, Barco, Landau, Koi, Dansko and many others, including exclusive merchandise that only Life carries including the new Laura Ashley line of medical scrubs. They also sell their own product line, Life Uniform, which reflects the Life philosophy of STYLE and VALUE.

For more information, visit Life Uniform or call Deb Weis, VP of Marketing at 314-824-2906.

About Laura Ashley
Laura Ashley, Inc., headquartered in Fort Mill, S.C., is the master franchising and licensing holder of the Laura Ashley brand in North and South America. The company strives to be the ultimate destination brand for home products, women’s wear and children’s wear. Licensed categories include bed linen, mattresses, women and children’s clothing and accessories, and much more. For additional information visit www.lauraashley-usa.com.

MIAMI, FL–(Marketwire – September 22, 2010) –  Simulated Environment Concepts (PINKSHEETS: SMEV) a/k/a SE Concepts, manufacturer and developer of medical, aesthetic and wellness equipment, announced that the Dermscan Group is close to wrapping up its clinical trial research on the SpaCapsule and the equipment’s medical benefits.

Dr. Ella Frenkel, Chairman and CEO of Simulated Environment Concepts, Inc. said, “SE Concepts tirelessly strives to develop products which return dividends to our customers by way of overall improved health. The Spa Capsule does just that. In allowing users to not only feel de-stressed and refreshed after each therapeutic session, but internally renewed, we’re able to deliver a product to the medical and wellness community that simply pays for itself.”

The international cosmetic and clinical research company, Dermscan, began its study during late spring of this year with an expected completion time of early to late October 2010. Due to the great emphasis on weight loss, cellulite reduction and therapeutic use in Europe, Dermscan took to task proving just a few of the medical benefits derived from using the SpaCapsule. Results of the study are anticipated to lend to the increasing international appeal of the SpaCapsule — possibly doubling its current global distribution commitment.

Dr. Ilya Spivak, Marketing Director and co-inventor of the SpaCapsule stated, “From this study we deduce that the Spa Capsule will continue to grow as a medical apparatus that is a ‘must have’ by the physical therapy, rehabilitation and pain management community. Being a doctor myself, many times I’ve witnessed the reversing affects that the Spa Capsule has on ailments. Frankly, it is quite amazing.”

Sources close to SE Concepts say the company is receiving much international fan fare from the incredible results achieved by those continuously using the Spa Capsule. It is strongly believed a positive reporting from Dermscan will continue to fuel the current growth of the product within the medical and wellness industries worldwide.

About Simulated Environment Concepts, Inc.

Simulated Environment Concepts, Inc. is the developer of a variety of products for wellness, relaxation, weight loss, and rehabilitation. Our aqua massage and hydromassage products are used by Doctors, Gyms, Spas, retail locations, offices, and many other venues. Incorporating oxygen, aromatherapy, massage, and even music or video from an iPod or an iPhone, our products deliver consistent results and excellent earning potential for businesses. For more information on Simulated Environment Concepts and its flagship product, SpaCapsule®, PTjetCapsule™, and Celude Laboratories™ products you can visit the company’s product website at www.spacapsule.com, the corporate website at www.seccorporation.com, or request more information via email at [email protected], or call at (888) 757-0797 or (305) 651-9200.

Safe Harbor

Statements in this news release that are not historical facts, including statements about plans and expectations regarding products and opportunities, demand and acceptance of new or existing products, capital resources and future financial results are forward-looking. Forward-looking statements involve risks and uncertainties which may cause the Company’s actual results in future periods to differ materially from those expressed. These uncertainties and risks include changing consumer preferences, lack of success of new products, loss of the Company’s customers, competition and other factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

SpaCapsule is registered trademark of Simulated Environment Concepts, Inc.

Click here to see all recent news from this company

SAN FRANCISCO, CA–(Marketwire – September 20, 2010) –  ORACLE OPENWORLD — Oracle (NASDAQ: ORCL)

News Facts

• Harvard Pilgrim Health Care, Inc., the number one commercial health plan in America for five straight years, according to U.S.News & World Report and the National Committee for Quality Assurance (NCQA), has chosen Oracle Health Insurance to build its core claims adjudication solution.
• The Oracle Health Insurance Claims solution will be the first application resulting from the combination of Oracle’s European health insurance market experience and intellectual property with the Oracle Insurance rules-based adaptive application strategy. The combination provides the foundation for the next generation of core Oracle Health Insurance applications, delivering the configurability required to address critical time-to-market issues for implementing new health benefits and those resulting from United States regulatory changes.
• The service-oriented-architecture (SOA)-based solution offers numerous integration points and a phased approach to system replacement, enabling Harvard Pilgrim to simplify and extend its existing multi-claims platform environment, reducing system integration and custom coding requirements, and ultimately its total cost of IT systems ownership.
• The solution supports the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10), which is mandated for adoption in the United States by 2013.
• Claims adjudication for all types of claims and alternative reimbursement models will be highly automated in the solution, minimizing the need for human intervention. This will enhance comprehensive straight-through processing capabilities, driving down claims processing costs.
• Critical back-office processes will be streamlined based on the solution’s integration with Harvard Pilgrim’s Oracle E-Business Suite (Oracle Financials).
• The solution will replace a legacy system that is not equipped to support the ICD-10 mandate and is costly to adapt to other new regulatory requirements and market challenges.
• The solution is being built by Oracle Health Insurance, a newly formed group within Oracle Insurance, the business unit created within Oracle to focus on the unique challenges of its global insurance customers.
• Dell Services, Harvard Pilgrim’s technology and business process outsourcing partner, will work with Oracle to implement the Oracle solution.

Supporting Quotes

• “U.S. health insurance payers are facing the most fundamental shift in their history. We must have systems to support rapidly changing product portfolios and the pending requirements of Federal healthcare reform,” said Deborah Norton, Chief Information Officer, Harvard Pilgrim Health Care, Inc. “Oracle’s European solution for claims adjudication, currently the dominant application in The Netherlands, addresses that hybrid public/private market with a uniquely flexible solution. Oracle’s proposal to combine this with a native service-oriented-architecture approach provides Harvard Pilgrim with a timely and compelling solution.”
• “Oracle Insurance welcomes the opportunity to collaborate with Harvard Pilgrim in a collaboration that represents our entry into the U.S. core health insurance applications market — an area in which Oracle Insurance sees extensive room for growth as insurers seek solutions to help them navigate major industry changes,” said Michiel Walsteijn, Senior Director, Oracle Health Insurance. “With Harvard Pilgrim, we will bring to life our vision of the adaptive health insurer, one that can be nimble and profitable while managing regulatory change.”

Supporting Resources

• Oracle Insurance
• Oracle Insurance on Twitter
• Join the Oracle Insurance Community on Facebook
• Join the Oracle Insurance Group on LinkedIn

About Oracle
Oracle (NASDAQ: ORCL) provides the most complete, open, and integrated business software and hardware systems in the world. For more information about Oracle, visit oracle.com

About Harvard Pilgrim
Harvard Pilgrim is a not-for-profit health plan that provides a variety of health benefit options and funding arrangements to more than one million members in Massachusetts, New Hampshire and Maine. Harvard Pilgrim, for the fifth consecutive year, was named the #1 commercial health plan in America according to a joint ranking by U.S.News & World Report and the National Committee for Quality Assurance (NCQA)*. For more information, please visit www.harvardpilgrim.org.

Trademark
Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

AUSTIN, TX–(Marketwire – September 20, 2010) –  RecMan Inc., today announced the availability of RecMan for Google Apps™, the world’s first web-based compliance and records management software designed to ensure policy and regulation compliance for millions of Google Apps™ users.

More than 20 million users within businesses, government agencies, schools and other organizations world-wide have switched to Google Apps. Unfortunately, many of them cannot use all of the applications within Google Apps since it does not have any built-in document compliance or records management features to meet organizational standards and legal regulations.

“By adding records management and compliance features to Google Apps, corporations, government and organizations of any size now have the ability to centrally apply document access control, retention and disposition policies. This enables compliance with HIPAA, Sarbanes Oxley, FERPA and other regulations, as well as internal policies,” says Richard Roberts, President and CEO of RecMan, Inc. “Records management and compliance features are usually only part of big expensive enterprise systems, but now those same capabilities are available in Google Apps for a fraction of the price.”

With the release of RecMan it can be expected that millions of additional users will flock to Google Apps, confident that they can be in full compliance with organization and government regulations.

On July 26, 2010 Google announced it was one of the first to receive certification and accreditation to provide cloud computing services to government agencies and private sector affiliations. Google is aware of the critical role that enterprise-grade records management and compliance occupies.

At the 2009 Gartner Symposium/ITxpo in Orlando, Eric Schmidt, CEO of Google, was asked how the company plans to meet compliance standards and regulations for information stored in the cloud. Schmidt responded that, “It’s time now for people to figure out how to take their business logic and connect it using our APIs to our underlying data stores,” thereby opening the door for third party vendors to help meet compliance needs.

The release of RecMan for Google Apps meets these needs and supports the three main standards for compliance and electronic records management including ISO 15489, DoD 5015.2 and MoReq2. RecMan for Google Apps enables records managers and compliance officers to easily and quickly apply organizational policies to all of the information stored in Google Apps.

RecMan for Google Apps meets five critical compliance needs espoused by ARMA International, the Association of Records Managers and Administrators, including a) centrally controlled document access management, b) document classification policy management, c) retention policy management, d) destruction and disposition policy management, e) legal hold management.

There is minimal training required to implement RecMan. Once the Records Manager or compliance officer sets up the policy information, users can drag and drop their document into the appropriate shared folder or choose it from the folder menu of Google Docs. The document then falls under the control of RecMan for Google Apps, enabling all of the access and retention policies of the organization to be applied automatically.

RecMan for Google Apps is available in the Google Apps Marketplace for $18 per user annually. It will also be available from a growing number of system integrators and resellers. For more information about RecMan for Google Apps, you can visit http://www.RecMan.net. 

About RecMan Inc.
RecMan Inc. is a venture funded start-up to provide world-class compliance and records management software. With offices in Austin, TX and Yokohama, Japan, RecMan was developed by Richard Roberts, the same designer that engineered the world’s first web-based compliance and records management software that is used by thousands of users world-wide. RecMan for Google Apps is the world’s first and only application that brings enterprise-grade records management and compliance to Google Apps.

Click here to see all recent news from this company

SILVER SPRING, MD–(Marketwire – September 20, 2010) –  The Association of Public Health Laboratories (APHL) and its members commend the 52 Members of the United States Senate who on September 14 voted against the elimination of funding for the Prevention and Public Health Fund, which was created in the Affordable Care Act (ACA), the federal health reform law. This action assures that much-needed increases in federal support for public health laboratory operations will occur in federal fiscal years 2010 – 2015; jobs will be saved, surveillance and detection of harmful outbreaks will be increased and the health of Americans will improve.

Voting on a procedural matter (Roll Call Vote #231), the Senate rejected an amendment offered by Senator Mike Johanns (R-Nebraska) that would have used the resources in the Fund as an off-set on a matter wholly unrelated to the health of Americans.

In federal fiscal year 2010, the Fund will provide an increase in resources of almost fifty percent for activities that will improve the surveillance and detection of foodborne disease outbreaks and of emerging and re-emerging infectious disease outbreaks, while advancing the completeness of electronic health records. It is likely that the Fund will supply a doubling of funding for these activities in federal fiscal year 2011.

The significance of the eight-vote margin by which the amendment was defeated is greater when the extraordinarily strong push by the business community for the amendment is considered. Even in the face of this great success, the public health community nonetheless remains vigilant for the likely continuous attempts to siphon off the Fund for other uses and all other attacks to overturn the ACA and harm the health of Americans.

“The public health community came together quickly and cohesively in the effort to protect the Prevention and Public Health Fund from this attack,” said APHL Executive Director Scott Becker. “This accomplishment will be easily replicated for any future attempts to reduce or eliminate the Fund and should send a very clear message to those who seek other uses for it: ‘Hands Off!'”

The Association of Public Health Laboratories is a national non-profit located in Silver Spring, MD, that is dedicated to working with members to strengthen governmental laboratories with a public health mandate. By promoting effective programs and public policy, APHL strives to provide public health laboratories with the resources and infrastructure needed to protect the health of US residents and to prevent and control disease globally.

Click here to see all recent news from this company

MENLO PARK, CA–(Marketwire – September 20, 2010) –  Allocade, Inc., the developer of healthcare’s most advanced tools to orchestrate patient flow, today announced that Children’s Hospital Boston plans to expand implementation of the On-Cue® Operations Management Software suite throughout its Radiology Department. Children’s Hospital Boston originally deployed On-Cue in the hospital’s Interventional Radiology (IR) and Magnetic Resonance Imaging (MRI) areas, and worked closely with Allocade to ensure that the application met the complex needs of a pediatric site.

On-Cue is powered by an Artificial Intelligence engine, which automatically adapts to disruptions as they occur. This generates the industry’s only Dynamic Patient Itinerary — a real time list of each patient’s procedures and related preparatory tasks.

“On-Cue helped to make our processes for communication more efficient,” said Sharon Silk, M.P.H., director, radiology quality management and operations improvement, Children’s Hospital Boston. “The new system offers an easy way to capture meaningful metrics, which are necessary for making operational improvements.”

“As a communication tool, the impact of implementing On-Cue was apparent immediately,” said Richard L. Robertson, Jr., M.D., acting radiologist-in-chief, Children’s Hospital Boston. “Within the first hours of go-live, the number of telephone calls between the control room and reading room decreased dramatically. The ability to see patient status at a glance and communicate directly with the technologists performing the exam allows the radiologists to focus on image interpretation, which leads to greater efficiency in patient turnover.”

The On-Cue core technology was conceived by Don Rosenthal, founder and chief technology officer of Allocade. At NASA, Rosenthal led the Artificial Intelligence Applications Group in the NASA Ames Research Center. He was also part of the team that developed the dynamic rescheduling software that optimally utilized the limited resources on the Hubble Space Telescope. The company’s patented Schedule Repair™ technology augments information already available in Hospital Information Systems (HIS), Radiology Information Systems (RIS) and Electronic Medical Record Systems (EMR), by adding a layer of intelligence to these systems.

About Allocade, Inc.
Allocade Inc., headquartered in Menlo Park, Calif., is a healthcare software company that develops tools to intelligently optimize patient flow throughout the hospital. The company’s first product is the On-Cue Hospital Operations Management system. Allocade’s management team includes former top executives from NASA Ames Research Center, Fujifilm Corporation, and Stentor. For more information about Allocade and the On-Cue Software Solution, visit www.allocade.com.

On-Cue is a registered trademark of Allocade, Inc.

DALLAS, TX–(Marketwire – September 16, 2010) – Addison Health Systems, Inc. (AHS), considered a pioneer (since 1996) of Electronic Health Records with its WritePad™ EHR product line, has applied on September 1^st for October 2010 EHR certification with the Austin-based Drummond Group, Inc. AHS has been very successful by offering unique capabilities for computerizing doctor specialties in pain management, alternative, sports medicine, behavioral psych, occupational and pain/rehab care.

The U.S. government announced in February of 2009, the American Recovery and Reinvestment Act (ARRA). The ARRA act included $19 billion under the portion of its HITECH Act to promote the adoption of Electronic Health Record (EHR) technology in healthcare. Starting in 2011, medical providers can receive up to $44,000 or more by demonstrating what has termed as “meaningful use” of certified EHR technology to be eligible for government funds. 

The U.S. Department of Health and Human Services (HHS), through its Office of National Coordinator for Health IT (ONC), has awarded certification accreditation to two organizations: The Certification Commission for Health Information Technology (CCHIT) and Drummond Group, Inc. Drummond Group announced it would be taking applications immediately while CCHIT will start taking applications on September 20, 2010. 

“It has been a long process of waiting for the ONC to determine what organizations would be put in charge of EHR accreditation. Thus AHS made the decision to move forward immediately with Drummond Group, Inc. on the 1^st allowable sign up date so our thousands of clients could be eligible for up $44,000 stimulus money,” said Greg Winterkamp, CEO/President of AHS. “In fact with our ePrescribing partner, WritePad will accomplish ARRA certification from both Drummond and CCHIT!”

Drummond Group brings years of government software certification experience to the table. The company had been involved with the ONC throughout its evaluation of certification organizations. CCHIT was originally appointed by the government in 2005 as the sole certification organization and had certified EHRs under the CCHIT-created guidelines. However, with the ARRA legislation, the federal government (ONC) was provided the authority to refine and add additional criteria that now make up the new meaningful use guidelines.

“I think it is crucial that an additional certifying organization was added. Competition brings down certifying costs and adds additional controls to define practical capability providers need for using an EHR. The term ‘meaningful use’ is a product of this.” Mr. Winterkamp added, “I was very skeptical when the government got involved in the definition of the certification guidelines however, I have been impressed that so much has been done in a short period of time. The Stage 1 guidelines that the ONC has defined for 2011 certification are helpful to allow many providers to incorporate EHRs in an efficient manner.”

Scott Giddiens, Director of Sales at AHS, stated, “We are proud that WritePad will be one of the first EHRs to be certified in the U.S.! That is very important for our clients and the many prospective doctors that have been sitting on the fence waiting, to get the assurance that our EHR will be government certified.”

About Addison Health Systems, Inc.

Addison Health Systems, Inc. has been in business since 1985. With the release of the WritePad’s EHR in 1996, AHS became a pioneer in computerizing doctors. The WritePad suite of products is being used by over 4,500 physicians and, with support staff, over 17,000 users daily for their clinical documentation needs. Patients can log into stations and fill out intake information that automatically updates into the doctor’s workflow of encounter data. WritePad is utilized by pain management, chiropractic, PMR, physical therapy, osteopathic and many other physical medicine and rehabilitative care facilities and hospitals. From electronic billing, practice management, EHR documentation, ePrescribing to 3-dimensional patient education and exercise videos, the WritePad increases clinical compliance, efficiency and 3^rd party reimbursements. For further information, visit http://www.writepad.com

Click here to see all recent news from this company

OAKLAND, CA–(Marketwire – September 16, 2010) –  Every day thousands of patients are readmitted to hospitals because they did not get adequate follow-up care following their previous hospitalization. In fact, 18% of patients are readmitted to a hospital within 30 days of discharge — and as many as 76% of these readmissions are preventable. The most recent national figures on health care expenditures indicate that unplanned hospital readmissions cost Medicare $17.4 billion in a single year. In its latest report, “Technologies for Improving Post-Acute Care Transitions,” the Center for Technology and Aging examines how the use of a variety of existing technologies could dramatically reduce readmissions.

“Several technologies are widely available and have potential to support post-acute care transitions, but they are underutilized,” said David Lindeman, Ph.D., Director of the Center for Technology and Aging. “Home-use technologies help decrease readmissions in a variety of ways, including engaging patients and caregivers in ways that promote better communication, medication adherence, and monitoring of chronic conditions.”

The complete report is available for download at www.techandaging.org.

The report covers four post-acute care transition (PACT) technology focus areas. Included is information such as technology definitions, how they are used in the home, their impact on readmissions, and charts that compare basic features of various technologies.

• Medication adherence technologies
  • Non-adherence is responsible for 33% to 69% of medication related hospital readmissions.
  • Four categories are described in a chart that lists sample technologies, pros/cons of each, market stage, economics, and what function each fills in the medication adherence spectrum.
• Medication reconciliation technologies
  • “Med-rec” seeks to reduce adverse drug events. Twenty percent of discharged patients experience an adverse event and 2/3 of those are medication related.
  • A chart lists seven tools that help patients maintain an accurate list of medications, a description of each tool, and the organizations sponsoring them.

(More on medication optimization technologies is available in the Center’s report, “Technologies for Optimizing Medication Use in Older Adults.”)

• Remote patient monitoring (RPM) technologies
  • A chart shows RPM capabilities and applications.
  • A discussion of the VHA’s use of and research on Health Buddy.
  • A chart describing seven popular remote patient monitoring devices: Health Buddy, Telestation, Genesis DM, Intel’s Health Guide, LifeView, Ideal LIFE Pod, and Healthanywhere.

(More information is available in the Center’s report, “Technologies for Remote Patient Monitoring in Older Adults.”)

• Health information and communication technologies (ICT)
  • Personal health records and information — includes a description of the Stepping Stones Project of Whatcom County.
  • Web-based social networking — including a description of Tyze, www.tyze.org, which provides secure, online personal support networks.
  • Remote training and supervision technologies — includes a description of Rest Assured, and a Visiting Nurse Service of New York demonstration project.

According to the report, ICT enables timely access to vital health information. It points out that when ICT is used in conjunction with devices that monitor health parameters in the home, care becomes continuous rather than episodic. And, according to Dr. Lindeman, “care becomes patient-centered, rather than facility-centered.”

The report includes a description of four well-known care transition models with varying use of home-based technologies. The models are: the Care Transitions Intervention (www.caretransitions.org), Guided Care (www.guidedcare.org), the Transitional Care Model (www.innovativecaremodels.com/care_models/21/overview), and Geriatric Resources for Assessment and Care of Elders (www.medicine.iupui.edu/iucar/research/grace.asp).

The Center for Technology and Aging (www.techandaging.org) supports more rapid adoption and diffusion of technologies that enhance independence and improve home and community-based care for older adults. Through grants, research, public policy involvement and development of practical tools and best practice guidelines, the Center serves as an independent, non-profit resource for improving the quality and cost-effectiveness of long-term care services. The Center was established with funding from The SCAN Foundation (www.thescanfoundation.org) and is affiliated with the Public Health Institute (www.phi.org) in Oakland, CA.

Click here to see all recent news from this company

POCATELLO, ID–(Marketwire – September 16, 2010) –  TetriDyn Solutions, Inc. (OTCBB: TDYS), announced today that it has delivered a proven virtualization solution targeted specifically for hospital environments like Harms Memorial Hospital in American Falls, Idaho. The virtualization solution is built using the industry’s leading platforms for its customers to achieve energy savings, faster application and service delivery, full IT management automation, and higher levels of business continuity.

Virtualization improves the efficiency of IT resources by eliminating “one physical server to one application paradigm” by running multiple virtual machines on each physical machine. A typical datacenter’s budget spends two-thirds of the budget maintaining existing infrastructure needs. Using virtual machines, virtualization delivers more efficiency and better response to the dynamic needs of an organization. Servers, applications, and desktops can be virtualized in minutes, deploying when and wherever they are needed.

The design for the Harm’s virtual environment was developed after an initial assessment of the existing infrastructure was developed as a baseline. After securing grant resources from the State of Idaho specifically identified for improving business and revenue flow for critical access hospitals, TetriDyn and Harms began designing Harms’ new high-efficiency virtual environment. Susan Barger, Director of Development at Harms, stated, “TetriDyn Solutions provided us with the technical information enabling us to win a grant that solidified our infrastructure in preparation for the inevitable EMR implementation.”

TetriDyn’s IT Services department guided Harms by providing education and experience through the design, securing the best purchase prices, and implementing the right virtualization technology for their environment. The results were dramatic. Infrastructure servers are now fully leveraged by increasing their utilization. Servers were consolidated, reducing points of failure, all while achieving more energy-efficiency for a greener environment.

TetriDyn adheres closely to following the system engineering lifecycle for producing successful technology implementations. The end goals of which are to ensure that the customer’s needs or requirements are met and the project risk is substantially reduced.

About TetriDyn Solutions, Inc.
TetriDyn Solutions, Inc. (OTCBB: TDYS) specializes in providing business information technology (IT) solutions to its customers. TetriDyn Solutions optimizes business and IT processes by utilizing systems engineering methodologies, strategic planning, and system integration to add efficiencies and value to its customers’ business processes and to help its customers identify critical success factors in their business. For more information about the company, visit www.tetridyn.com.

RIVERSIDE, CA–(Marketwire – September 16, 2010) –  ONRAD, Inc., a leading radiology services provider, announces support for the National Rural Health Association (NRHA) by exhibiting at the Critical Access Hospital and Rural Health Clinic Conference in Kansas City, MO. 

Visit ONRAD at booth #221 to learn about the company’s complete teleradiology solution for critical access facilities, which can include standard teleradiology services, subspecialty teleradiology interpretations, professional radiology staffing, and technology consulting.

As a national radiology services provider, ONRAD’s team understands the challenges associated with staffing radiologists in rural locations. “ONRAD’s technology allows the radiology group to provide services to any location,” said Dr. Alix Vincent, Vice President of Medical Affairs at ONRAD. “We are even able to offer subspecialty expertise in the most difficult to staff areas including MSK and mammography.” 

“It is important that all patients have access to quality radiology services, regardless of where they are located, and ONRAD will continue to offer turnkey solutions to critical access hospitals at the most competitive prices,” said Dr. Vincent of the company’s dedication to working with rural facilities across the U.S.

About ONRAD: ONRAD is a full service physician-owned radiology provider offering customized radiology services including teleradiology solutions, professional radiology staffing, subspecialty teleradiology interpretations, and technology consulting. As a partner, ONRAD helps its customers be more competitive in their local markets by complementing and expanding the radiology services already in place, or providing a comprehensive solution.

About NRHA: The National Rural Health Association (NRHA) is a national nonprofit membership organization with more than 20,000 members. The association’s mission is to provide leadership on rural health issues. NRHA membership consists of a diverse collection of individuals and organizations, all of whom share the common bond of an interest in rural health.

Click here to see all recent news from this company

UTICA, NY–(Marketwire – September 15, 2010) –  CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the Company will participate in the UBS Global Life Sciences Conference, on Monday, September 20, 2010 at 2:00 PM Eastern time. The event will be held in New York at the Grand Hyatt Hotel.

Mr. Joseph J. Corasanti, President and Chief Executive Officer of CONMED, will discuss the Company’s business. The live webcast of CONMED’s presentation will be available at www.conmed.com in the Investor Relations – Events Calendar section of the website and will be available for replay through September 30, 2010.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use the Company’s medical devices. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations.

Forward Looking Information

Certain statements made in the presentation may constitute forward-looking statements. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. They will be based upon management’s expectations and involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements therein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to: (i) the failure of any one or more of management’s assumptions to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and Quarterly Reports on Form 10-Q; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition (and its integration) or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation, or litigation; and/or (viii) the Company’s ability to devise and execute strategies to respond to market conditions.

CAMBRIDGE, MA–(Marketwire – September 15, 2010) –  BestNursingDegree.com, a comprehensive online resource for nursing education, today announced the recipients of the 2010 “Back to School” Nursing Scholarships.

Scholarships of $2,500 each were awarded to one current registered nurse enrolling in an RN to BSN program, and one aspiring registered nurse enrolling in a second degree nursing program. The winners, chosen from a pool of over 600 applicants, are Adelpha Abrahamson Larkin of San Carlos, California, and Sheryll Brown of Tallahassee, Florida. Recipients were selected on the basis of a number of factors, including academic achievements and extracurricular activities. “We are pleased to congratulate Adelpha and Sheryll on winning the scholarships,” said Joseph Deal, the founder of BestNursingDegree.com. “We had a large pool of well-qualified applicants, and we wish all of them the best of luck in their studies.”

The scholarship was created in response to the ongoing nursing shortage and is an effort to enable more students to pursue nursing education. The program was administered by Scholarship America, the nation’s premier administrator of private scholarships. The application process for the next round of the “Back to School” Nursing Scholarships will begin in March 2011.

About BestNursingDegree.com:

BestNursingDegree.com strives to be the most comprehensive nursing education resource on the Web. Its directory includes more than 7,700 on-campus and online nursing degree programs from more than 2,300 schools across the United States. The website also features expert articles, interviews and career information. For more information, please visit www.bestnursingdegree.com.

Click here to see all recent news from this company

WASHINGTON, DC–(Marketwire – September 15, 2010) –

About Surescripts
Surescripts operates the nation’s largest e-prescription network and supports the most comprehensive ecosystem of health care organizations nationwide. Surescripts was founded on the principles of neutrality, transparency, interoperability, efficiency, collaboration and quality. Surescripts connects prescribers in all 50 states through their choice of e-prescribing software to the nation’s leading payers, chain pharmacies and independent pharmacies. The Nation’s E-Prescription Network is available every day to healthcare providers in need of low-cost, electronic access to prescription and health information. By securely and reliably providing that information during emergencies and routine care, Surescripts is committed to saving lives, improving efficiency and reducing the cost of health care for all. For more information, go to www.surescripts.com and follow us at twitter.com/surescripts.

CALABASAS, CA–(Marketwire – September 15, 2010) – The McKenzie Institute has long been recognized as a leader in the professional development of physical therapists, especially in what has become known as the “McKenzie Method.” A recent partnership agreement with continuing education provider EDUCATA widens the scope of courses offered by the Institute to include EDUCATA’s interactive content, and exposes its own classes to the large number of EDUCATA members.

“Post-grad education for clinicians has been the cornerstone of our Institute since the mid 1950’s, when our highly-effective and evidence-based method of assessment, diagnosis and treatment for the spine and extremities was developed,” said Stacey Lyon, Executive Director of The McKenzie Institute USA. “Partnering with EDUCATA allows us to build on this foundation with additional courses that meet our standards of quality and boost our Mechanical Diagnosis and Therapy (MDT) Certification curriculum.”

“We are extremely proud of counting McKenzie among our partners,” said Dr. Marilyn Pink, EDUCATA President and CEO. “The Institute represents all that we value in the education of the therapist: a truly professional approach that delivers evidence-based content to PTs around the world.”

Under the terms of the agreement, EDUCATA courses will be accessed from the education channel at mckenziemdt.org and McKenzie courses will form part of EDUCATA’s catalog of offered classes.

About The McKenzie Institute: The McKenzie Institute USA, founded in 1982 as the first official branch and recognized as 501(c)3 not-for-profit, is one of 26 branches worldwide that train and certify physical therapists and other healthcare professionals through its multi-level educational curriculum. The Institute was proud to add an APTA and AAOMPT approved Fellowship Program in MDT in 2008.

About EDUCATA:  EDUCATA.COM is a unique, interactive, Web 2.0 education platform that delivers online learning. It offers a broad spectrum of courses from orthopaedics and pulmonology to geriatrics and oncology that are taught by top-ranked educators and experienced clinicians. EDUCATA’s partners include the World Confederation for Physical Therapy and many APTA chapters and sections. The company is a leader in providing continuing education for physical therapists and other medical professionals. 

Click here to see all recent news from this company

ATLANTA, GA–(Marketwire – September 15, 2010) –  The following is a letter to shareholders from the CEO of ALR Technologies.

Dear Shareholders:

As ALR Technologies (OTCBB: ALRT) is entering a new phase of business development, I am writing to report on our progress. The Company is preparing to launch the ALRT Health-e-Connect (HeC) System, a system that tracks adherence to care plans of patients with chronic conditions. The Company has extensive experience in developing medication reminders and ALRT has added the ability to remotely collect data from medical devices in the new HeC System.

A 510(k) was filed for the HeC System with the FDA on July 23, 2010. We expect clearance before the end of 2010. The HeC may be offered for sale in the U.S. when it receives 510(k) clearance.

Initially, our efforts will be focused on treatment of diabetes. This is because the disease has reached pandemic proportions globally. There are many complications related to the disease and it is the most expensive chronic condition to treat. 

The effectiveness of diabetes treatment can be measured by improvements in A1C (a long-term measure of control over blood glucose). According to the Centers for Disease Control and Prevention, “in general, every percentage point drop in A1C blood test results (e.g., from 8.0% to 7.0%) can reduce the risk of microvascular complications (eye, kidney, and nerve diseases) by 40%.”¹ The ALRT HeC System has shown in a clinical trial to reduce A1C by 1.2%².

Using the HeC with current medical protocols could mean billions of dollars in savings for just the treatment of diabetes. 

Two landmark diabetes studies³ concluded that intensive glucose control could delay or possibly even prevent diabetes-related complications. The HeC System has shown to be a platform that can be successfully used for intensive glucose control.

Importantly, the HeC can be deployed for intensive glucose control for diabetes treatment without involving frequent time consuming and expensive visits with the patients. Therefore, the HeC would offer healthcare providers with an efficient way of treating patients and would also be affordable to payers. The HeC can easily be implemented for all who care for diabetes patients⁴.

Intensive glucose control puts a diabetes patient in charge of his condition. According to an estimate by Health Partners, a diabetes patient who is in control of his condition might incur $5,000 in costs per year, but a patient who is not could incur costs up to $45,000 annually⁵ due to emergency room visits and hospital stays — not to mention lost productivity.

The Company is currently pursuing reimbursement opportunities, which will allow healthcare providers to receive appropriate compensation for providing affordable intensive glucose control to their patients. This in turn will also benefit public and private healthcare insurers by helping them to realize substantial cost savings. The prospective reimbursement for intensive glucose control using the HeC could stimulate and accelerate early adoption of the HeC System by providing healthcare providers who treat diabetes patients with a new source of revenue.

ALRT is continuing to support clinical trials and research. In addition to the clinical trial mentioned above, a different pilot sponsored by the Company⁶ showed that average A1C scores dropped from 7.6 to 6.7 over a 3 month period. At the same time, average frequency of self-testing for blood sugar increased from 1.4 times per day to 3.1 per day. HeC is also designed to accurately measure the frequency of self-testing, and ALRT is supporting a new clinical trial to measure frequency of self-testing and its impact on A1C.

At ALRT, we are excited and encouraged by the prospects for the Company and look forward to being an important partner in containing treatment costs of chronic diseases, especially diabetes in the U.S. and other countries. Thank you all for your continued support. As we move ever closer to bringing our vision to reality, we anticipate realizing the rewards from the great potential of the ALRT Health-e-Connect (HeC) System. A visit to our website, www.alrt.com, will give you a good representation of the capabilities and impact of our exciting product.

Yours truly,
ALR TECHNOLOGIES INC.

Sidney S Chan
Chairman & CEO 

About ALR Technologies Inc.
ALRT Health-e-Connect (HeC) System is the principal product of the Company. HeC is a web based application for medical professionals to improve compliance and adherence of care plans of patients in their homes. HeC is programmed to assist healthcare providers caring for diabetes patients. The platform will be expanded to cover patients with other chronic diseases. More information on ALR Technologies and its products can be found at http://www.alrt.com. 

This release contains certain “forward-looking statements” relating to ALR Technologies’ business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words “estimate”, “expect”, “anticipate”, “believe” and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company’s quarterly filings with the Securities Exchange Commission.

¹ Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008. (Page 11-12)
² Tildesley HD, Mazanderani AB, Ross SA; Effect of Internet therapeutic intervention on A1C levels in patients with type 2 diabetes treated with insulin; Diabetes Care. 2010 Aug;33(8):1738-40
³ DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study; National Diabetes Information Clearinghouse (NDIC) A service of the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), NIH; http://diabetes.niddk.nih.gov/dm/pubs/control/
⁴ ALR Technologies Inc. Press Release; http://www.marketwire.com/press-release/Features-of-the-ALRT-Health-e-Connect-HeC-System-for-Intensive-Diabetes-Treatment-1306468.htm
⁵ Health Partners. Beyond Benefits. January 2006. http://www.healthpartners.com:747/media/beyondbenefits/BB0106_br.htm Last accessed 8/13/10
⁶ ALR Technologies Inc. Press Release; http://www.marketwire.com/press-release/Average-A1c-Reduced-From-76-67-After-Three-Months-Initial-Report-ECHO-Employers-Coalition-927781.htm

MARKHAM, ONTARIO–(Marketwire – Sept. 15, 2010) – Leisureworld Senior Care Corporation (TSX:LW) today announced that the Company’s dividend for September, 2010 will be $0.0708 per share, representing $0.85 per share on an annualized basis. Payment will be made on October 15, 2010 to shareholders of record September 30, 2010.

About Leisureworld

Leisureworld is the third largest licensed long-term care (LTC) provider in Ontario. The Company owns and operates 26 LTC homes, representing approximately 4,314 beds across Ontario, Canada. Leisureworld also owns and operates one retirement home with 29 beds and one independent living home with 53 apartments. Leisureworld subsidiaries include: Preferred Health Care Services, an accredited provider of professional nursing and personal support services, Ontario Long Term Care, a provider of purchasing services, dietary, social work, and other regulated health professional services, and Tealwood Developments, a provider of laundry services to the Leisureworld Homes.

PITTSBURGH, PA–(Marketwire – September 15, 2010) –  Privately owned Deaf-Talk LLC dba DT Interpreting, the industry leader in on-demand video sign language interpreting, announced today that, pursuant to a stock exchange agreement, it has completed a reverse merger with Morgan Equities Group, Inc., a public company. Over ten-years old, DT Interpreting provides around the clock nationwide in-hospital interpreting services for the deaf. The newly merged company is named Deaf-Talk, Inc. and trades under the symbol (PINKSHEETS: MGQG). Deaf-Talk markets its services as DT Interpreting.

“DT Interpreting is the largest, fastest-growing company in its field with almost 400 hospital installations concentrated in the eastern and southern United States,” stated David Stauffer, executive vice president. “The company, which derives a large portion of its revenue from three-year contracts, now plans to market its services throughout the US southwest and entire western seaboard, with emphasis on California and Texas.”

DT Interpreting President, Robert Fisher, added: “The company attributes its leading market position to the integration of solid technology with certified sign language interpreters, which makes the communication between health care professionals and the deaf easy and timely. This is particularly important in emergencies when a few short minutes could be the difference between life and death.”

In addition to its video sign language interpreting, DT Interpreting also offers on-demand over-the-phone interpreting in more than 150 languages, full-scale document translation services and transcription into Braille.

More information about DT Interpreting can be found on the Company’s website: www.dtinterpreting.com.

About DT Interpreting
Founded in 1999 and now the industry leader, publicly-traded DT Interpreting is headquartered in Pittsburgh, PA with sales and customer service offices in Connecticut, Ohio and North Carolina. The Company provides on-demand video sign language and over the phone language interpretation, as well as full-scale document translation and translations into Braille.

Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Deaf Talk, Inc. dba DT Interpreting, which involves risks and uncertainties. The Company’s actual future results could materially differ from those discussed. The Company intends that such statements about the Company’s future expectations, including future revenues and earnings, and all other forward-looking statements be subject to the “Safe Harbors” provision of the Private Securities Litigation Reform Act of 1995.

Click here to see all recent news from this company

ALISO VIEJO, CA–(Marketwire – September 15, 2010) –  ExtendCredit.com, an online provider of customer financing plans for small and mid-sized businesses, today announced a new program designed to help Veterinarians and Animal Hospitals looking for an alternative to conventional third-party financing offer their own extended payment terms to pet owners. ExtendCredit.com is seeking to enroll veterinarians and animal hospitals in ExtendCredit.com’s Pet Healthcare Payment Plan program while also educating pet owners to ask their pet’s doctor or local animal hospital to offer affordable payment plans for pet healthcare.

Veterinarians and animal hospital administrators can sign up for the new program at www.extendcredit.com/petcare-credit.html or by calling (888) 364-2808.

“We recognize that pets are part of the family, and like any family member, pets sometimes need an emergency medical procedure to relieve suffering from a very treatable illness or injury,” said Joe Simrell, Co-President, ExtendCredit.com. “But unlike other family members, pets aren’t covered by the family’s medical insurance and pet insurance typically does not cover enough of the bill. In today’s tough economy, pet owners face hard choices about how they intend to pay for an emergency surgical procedure for their pet. Using a veterinarian or animal hospital that offers our payment plan program, they can get authorized for the procedure and pay for it without breaking their budget.”

According to Simrell, most pet owners have no plan for dealing with a serious health issue for their pet or pets. Those that do, and use conventional third party financing or have a pet insurance plan, find that those options are often inadequate for their needs. He notes conventional third party financing approval rates have dropped off as the credit markets have tightened. Only a small number of those who apply for these programs today are eligible and most have to have a high credit score to qualify. And even then, only certain procedures are covered. With ExtendCredit.com’s Pet Healthcare Payment Plan program, extended payment terms are mutually agreed upon between the veterinarian/animal hospital and the pet owner and ExtendCredit.com handles everything from there.

When there’s a pet health emergency, usually from a pet that’s been struck by a car, most animal hospitals charge $100 to $300 for an examination fee. A surgical procedure can range $500 to $5,000 depending on the ailment. There’s an old expression: “can’t afford the Vet, can’t afford the pet.” For pet owners suddenly faced with an unexpected veterinarian bill, ExtendCredit.com’s advice is to ask about financing plans up front. And to encourage their Veterinarian and Animal Hospital to use ExtendCredit.com’s automated payment plan service.

While pet owners consider their pets part of the family, in the eyes of the law, a pet is property. But unlike having a watch or TV set repaired, Veterinarians and Animal Hospitals release pets to their owners when they are well enough to go home. It’s then very difficult to make sure a pet owner pays the cost of the pet’s care. With ExtendCredit.com payment plans, the pet owner gets a payment they can afford, while veterinarians and animal hospitals can earn additional revenue through modest finance charges.

Click here to watch a short video about the program, or to sign up for the program, Veterinarians and Animal Hospital administrators can go to www.extendcredit.com/petcare-credit.html or call (888) 364-2808.

About ExtendCredit.com
Based in Southern California, ExtendCredit.com is a fully automated, online service that makes it easy for small and mid-sized businesses to create and manage their own payment plans for professional services and products.

ExtendCredit.com puts the business in control of their customer financing making it an effective, affordable, easy-to-use alternative to the high cost and complexity of bank and credit card lending in today’s tightened credit market. Businesses control the terms offered and who gets approved, while ExtendCredit.com provides all the tools needed to be successful, stay in control, and fully comply with lending laws.

ExtendCredit.com is used by businesses throughout the United States, most notably in the healthcare, animal care, services, and retail industries. ExtendCredit.com is a division of BillWise, Inc., and is headquartered in Aliso Viejo, California. More information is available at www.extendcredit.com.

Click here to see all recent news from this company

SAN FERNANDO, CA–(Marketwire – September 15, 2010) –  Precision Dynamics Corporation, the global leader in healthcare identification solutions, has been awarded a 3-year contract extension from Amerinet for patient wristbands, allowing Amerinet customers to lock in significant potential savings. Amerinet is a leading national healthcare group purchasing organization with more than 2,500 acute care hospitals and 25,000 alternate care members in its network of healthcare providers.

The Contract VH2100 for wristbands is active through October 31, 2013. It provides Amerinet clients with access to Precision Dynamics’ leading line of ID solutions for accurate, reliable and easy-to-use positive patient identification throughout the continuum of care, helping to prevent errors and improve clinical outcomes.

The agreement will help Amerinet clients continue to enhance their operating margins and cash flow. New cost savings include a committed Tier that will pass on a minimum savings of 10% off the standard Amerinet contract for those members who meet the requirements of Precision Dynamics’ PowerPlus™ Purchasing Program.

“As a partner with Amerinet for over 10 years, Precision Dynamics shares Amerinet’s goal of providing high quality care through positive ID solutions, while reducing costs and streamlining operations in healthcare,” said Gary Hutchinson, President and CEO of Precision Dynamics. “We look forward to our continued collaboration to provide positive ID and positive outcomes.”

Precision Dynamics was awarded the wristband contract as part of Amerinet’s intensive contract selection process, which focuses on delivering high quality, cost-effective solutions to the healthcare industry. Precision Dynamics is also under contract with Amerinet for its labeling solutions (contract VH05600).

About Precision Dynamics Corporation (PDC):
The Leading Provider of Positive ID and Positive Outcomes™
With more than 50 years of experience, Precision Dynamics provides accurate, reliable, and easy-to-use healthcare ID solutions that empower the flawless delivery of care and enhance outcomes across all major hospital functions. PDC products are used in all of the leading hospitals worldwide and comprise a comprehensive range of wristband and labeling systems that provide positive ID and positive clinical outcomes.

Precision Dynamics products meet important guidelines of the Joint Commission, World Healthcare Organization, FDA, AHA, and HIPAA. As the developer of the first single-piece patient wristband, the first bar code wristband system, and the first Smart Band^® RFID wristband system, Precision Dynamics solutions are an integral part of some of the most successful patient safety initiatives. As an ISO 9001 certified company, Precision Dynamics follows a systematic, world-standard approach to ensure superior product design, manufacturing, and customer supper services. Precision Dynamics constantly thrives to better understand customer needs and measures performance through vehicles such as its Customer Council and Customer Survey Program. For more information, call 800.772.1122 or visit www.pdcorp.com/healthcare.

About Amerinet
As a leading national healthcare group purchasing organization, Amerinet strategically partners with acute and alternate care providers to reduce costs and improve quality through its performance solutions. Built on a foundation of data, savings and trust, and supported by a team of clinical and supply chain experts, Amerinet enriches healthcare delivery for its members and the communities they serve. To learn more about the Amerinet difference, visit www.amerinet-gpo.com.

Precision Dynamics Corporation, product names, company names, marks, logos and symbols mentioned herein are trademarks or registered trademarks of Precision Dynamics Corporation. All other product names, company names, marks, logos and symbols mentioned herein are trademarks of their respective owners.

LONDON, ENGLAND–(Marketwire – Sept. 15, 2010) – George Michael’s accident highlights the possible dangers of driving with cannabinoids in the blood. Under UK law this in itself is not an offence, however, if the driver is impaired due to the cannabinoids, then this creates an offence.

The UK has recently approved the use of a cannabinoid spray for the treatment of spasticity in patients with Multiple Sclerosis. 

The Summary of Product Characteristics of this compound, which is the information that the regulatory authority approves to give to doctors, states in relation to Sativex and driving that ‘Sativex may produce undesirable effects such as dizziness and somnolence which may impair judgement and performance of skilled tasks. Patients should not drive, operate machinery or engage in any hazardous activity if they are experiencing any significant CNS effects such as dizziness or somnolence. Patients should be aware that Sativex has been known to cause a few cases of loss of consciousness’.

The Patient Information Leaflet which patients are given says that ‘You must not drive or use machinery when you first start to take Sativex and until you are established on a stable daily dose. Sativex may cause you to feel sleepy or dizzy, which may impair your judgment and performance of skilled tasks. It has also rarely been reported to cause a brief loss of consciousness. Once you are more used to taking Sativex and your dose is stable, you should still not drive or use machinery if Sativex causes effects such as sleepiness or dizziness that could impair your ability to perform these tasks. If you are not sure, do not drive or operate machines’.

Dr Malcolm VandenBurg who has given many medico legal opinions involving patients who have been prosecuted for driving with active and inactive cannabinoids in the system has given many opinions for the defence where patients have been prosecuted when their blood only contains inactive cannabinoids and there has been no evidence of impairment states that “thus patients are not told not to drive and the Medicines and Healthcare products Regulatory Agency (MHRA) seem content with this warning. That is like telling people who have drank alcohol that they are safe to drive unless they themselves feel impaired. How can that be right? 

The argument put forward is that the spray produces such a low concentration and clinical evidence suggests patients are unlikely to be effected, however, plasma levels in some patients reach concentrations which may impair driving skills and it is possible that they will not be aware of this.

The manufactures and MHRA also took into account the research evidence which did not show in many patients substantial impairment. However, some will be impaired. To leave it up to the patient is absurd.” 

Dr Malcolm VandenBurg wonders about the difference between legal Sativex and illegal smoking because as in the UK it is illegal to drive under the influence of substances such as illegal cannabis, it is interesting to know what position the courts will take if patients have accidents while their blood or urine shows they have cannabis in the body related to the prescription medicine.

If they are impaired, it is likely they could be prosecuted. It is interesting to postulate, but not useful as to what view the court will take.

“How can it be legal to drive when impaired after smoking cannabis and not be illegal to drive after using prescription cannabis? The manufacturers and MHRA have created this paradox. They should have warned patients not to drive.” 

Dr Malcolm VandenBurg points out that the product licence holders and the MHRA obviously accept that Sativex may be psychoactive but wonders why these same warnings are not given in the Summary of Product Characteristics and the Patient Information Leaflet, they are clearly different. How can doctors be told something different from patients.

“Despite the obvious psychoactivity of Sativex, the manufacturers and MHRA argue that they have taken the warning from other psychoactive medications such as the benzodiazepines where it is left up to the patient. However, although the warning to doctors is similar, the warning to patients is far more complicated. They thus acknowledge there is some danger. However, this could also be argued to be inadequate and our roads would certainly be safer if there was zero tolerance to both cannabis and benzodiazepines.”

NEEDHAM, MA–(Marketwire – September 14, 2010) –  The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), a private foundation funding collaborative translational science programs, announced today an important new publication in the September 8, 2010 online issue of the journal Science Express. The paper, co-authored by AMRF-funded scientists Victor Velculescu of Johns Hopkins University and Dennis Slamon of the University of California, Los Angeles, identifies two genes not previously implicated in ovarian clear cell carcinoma (OCCC). This finding provides two novel targets for the development of new drugs to treat this aggressive form of ovarian cancer that is generally resistant to current therapies.

“The collaboration among Drs. Velculescu, Slamon and their other Adelson Medical Research Foundation-funded colleagues brings together distinguished laboratories with capabilities in cancer genomics, genetics, and the treatment of cancer in women to uniquely analyze ovarian tumors,” said Dr. Miriam Adelson, Trustee and Executive Director of the Foundation. “This is an example of our Foundation’s unique collaborative model in action,” noted Sheldon G. Adelson, Trustee of the Foundation and Chairman of the Board and Chief Executive Officer of Las Vegas Sands Corp. “By funding collaborative teams from a number of major biomedical research institutions and a variety of scientific disciplines, we are bringing new insights to some of the most challenging areas of cancer research,” Dr. Adelson elaborated.

“This study implicates PPP2R1A as a novel oncogene and ARID1A as a novel tumor suppressor gene in OCCC, neither of which had previously been implicated in ovarian cancer,” noted Dr. Kenneth H. Fasman, Vice President and Chief Scientific Officer of AMRF. “This opens the door for two new directions in cancer drug discovery,” Fasman said.

Victor E. Velculescu, M.D., Ph.D., is Associate Professor of Oncology and Director of Cancer Genetics at the Ludwig Center for Cancer Genetics and Therapeutics of the Johns Hopkins Kimmel Cancer Center. He has co-authored many seminal papers on cancer genomics with his Hopkins co-authors Bert Vogelstein and Kenneth W. Kinzler. Dennis J. Slamon, M.D., Ph.D., is director of Clinical/Translational Research, and director of the Revlon/UCLA Women’s Cancer Research Program at the Jonsson Comprehensive Cancer Center. He is Professor of Medicine, chief of the Division of Hematology/Oncology and Executive Vice Chair for Research for UCLA’s Department of Medicine. For 12 years, Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. Drs. Velculescu and Slamon are members of the Adelson Medical Research Foundation’s ovarian cancer research collaboration.

The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, established in 2006, is a private foundation committed to a model of open and highly integrated collaboration among outstanding investigators who participate in goal-directed basic and clinical research to prevent, reduce or eliminate disabling and life-threatening illness. The Foundation creates a culture of scientific discovery, evaluation, and clinical application directed by the experiences of scientists who are not bound by searching for the cure of any single disease. Programs within the Foundation are defined in broad terms. The Adelson Program in Cancer Research pursues therapies targeted to the mechanisms that make cells malignant, and the Adelson Program in Neural Repair and Rehabilitation seeks to manipulate the regeneration of axons in the brain, spinal cord and peripheral nerves.

For additional information on the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, please visit www.adelsonfoundation.org/AMRF.

MUNDELEIN, IL–(Marketwire – September 14, 2010) – Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies, announced today the signing of a three-year national agreement with Premier Purchasing Partners, the group purchasing unit of Premier, Inc., to provide surgical mesh biomaterials used in soft tissue reinforcement to the more than 2,200 U.S. hospitals and 58,000 healthcare sites that are members of the Premier healthcare alliance. The agreement, which takes effect October 1, 2010, includes MotifMESH^® and VitaMESH^® products for the repair and reinforcement of hernia and other fascial defects.

“We’re very pleased to have been chosen for this contract award based on our shared values of providing great patient care while reducing overall healthcare costs,” said Marc Lessem, Medline’s Vice President of Advanced Wound Care. “Our innovative surgical mesh solutions give Premier members an efficient and effective way to improve patient outcomes in this growing arena.”

Ventral hernia repairs account for approximately 420,000 hernia repair operations annually in the U.S.¹ When a ventral hernia occurs, it usually arises in the abdominal wall where the muscle has weakened or where a previous surgical incision was made.² 

MotifMESH^® is an ideal mesh for ventral hernia repair because it is made from a unique “condensed” polytetrafluoroethylene (cPTFE) polymer. It has a macroporous structure which allows rapid incorporation into the abdominal wall while offering a reduction in adhesion formation to the cPTFE surface. It is the thinnest mesh available for ventral hernia repair at nearly 10X thinner than the two most commonly promoted intra-abdominal meshes.

More common than ventral hernias are inguinal (or groin) hernias, which account for approximately 700,000 hernia operations annually in the U.S.³ Statistically, the lifetime chance of having an inguinal hernia is 27 percent for men and 3 percent for women.⁴ The surgical operation is intended to repair a protrusion of abdominal-cavity contents occurring through the inguinal canal. VitaMESH is a strong, lower weight, transparent and easy to manipulate condensed polypropylene material making it a perfect choice for both laparoscopic and open hernia repairs. It is comprised of large interstices providing excellent visibility through the mesh forming a strong, fibrous wall.

About Premier, Inc.
The Premier healthcare alliance includes more than 2,200 U.S. hospitals and 58,000-plus other healthcare sites working together to improve healthcare quality and affordability. Premier maintains the nation’s most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier works with the Centers for Medicare & Medicaid Services (CMS) and the United Kingdom’s National Health Service Northwest to improve hospital performance.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, IL, Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities, and on-staff clinicians.

MINNEAPOLIS, MN–(Marketwire – September 14, 2010) –  Flu shot season is here and Health Fair 11 is ready to hold its annual Flu Fighter clinics. But before you head out to get your annual vaccination, there are some important changes to know about.

1. Flu Fighter clinics have new host sites. In September, MVNA nurses will be giving flu shots at all Minnesota Life Time Fitness locations. In October, vaccinations will be available at all YMCA centers in the Twin Cities and western Wisconsin. Club memberships are NOT required to attend Flu Fighter clinics.

2. Everyone is currently eligible to get a flu shot.  The Centers for Disease Control & Prevention (CDC) has changed its vaccination directives for this year. Priority groups have been eliminated. The CDC encourages everyone to be vaccinated as soon as flu shot clinics begin.

3. Most will only need one shot this year. The H1N1 influenza vaccine is contained in this year’s seasonal flu vaccine. Parents should consult with medical professionals to determine if their children will need more than one dose of seasonal flu vaccine. 

Vaccinations are given by registered nurses working for the Minnesota Visiting Nurse Agency. The MVNA is a nonprofit organization that uses all proceeds from the Flu Fighter clinics to fund its nursing care programs for thousands of Minnesotans who are ill, disabled, living in poverty, or in need of home care services. Learn more about MVNA and its services at www.mvna.org

Flu Fighter clinic dates & hours
Minnesota Life Time Fitness clubs — September 16 – 18 & September 23 – 26, 2010

Thursdays & Fridays: 4:00 – 8:00 p.m. Saturdays: 10:00 a.m. – 2:00 p.m.

 Metro area YMCA centers — October 14 – 16 & October 21 – 23, 2010

Thursdays & Fridays: 4:00 – 8:00 p.m. Saturdays: 10:00 a.m. – 2:00 p.m.

Flu Fighter clinics are open to anyone age 3 and older. Minors must be accompanied by a parent or guardian.

COST
Most health insurance plans will cover the cost of a seasonal flu shot. Bring your insurance card if you have one of these plans: Medicare, UCare, Advantra Freedom, Aetna, Blue Cross/Blue Shield, Cigna, Health Partners, Humana, Labor Care, Medica, MCHA-Medica, MHP, MN Health Care, Preferred One, Select Care, Unicare, and United Health Care.

People paying cash will be charged $26. FluMist ® nasal vaccine will be available for $32.

The Flu Fighter clinics are made possible by Health Fair 11, a nonprofit organization that operates with the support of KARE 11 TV, North Memorial, and UCare. Since 1998, more than 850,000 flu shots have been administered at Health Fair 11’s Flu Fighter clinics.

PITTSBURGH, PA–(Marketwire – September 14, 2010) –  pihms, Inc. (www.pihms.com), a leading provider of integrated software solutions for tracking, measuring and managing human capital through pihms Leave Management, pihms Safety Solutions, and pihms Care Solutions, announced today that it has signed another new client contract and two relationship renewal and service expansions.

New Client
pihms’ new client contract is to provide Leave and Case Management support tools for the more than 15,000 U.S. based employees of the $10+ billion U.S. affiliate of a global company.

The Company reported that its newest client began its vendor selection with the goal of providing better internal customer service to its employees as they navigate through the process of requesting and securing approval for leaves. Patrick J. Kalnas, President and CEO of pihms, said, “Of great importance to this client, was the fact that our Leave and Case Management solution is not only customer friendly for both employee and management, but will help their organization reduce costs related to inappropriate and excessive leaves.”

Client Renewals and Expansions
The first current client, an integrated energy utility company, is renewing the pihms services provided to their onsite employee health clinic, and expanding the relationship by adding pihms’ integrated comprehensive Leave and Case Management Solutions for their entire base of U.S. employees. 

The other client, the North American entity of a global automotive corporation, is continuing its five plus year utilization of pihmsSafety Solutions™ for its multiple U.S. manufacturing facilities. The enhanced relationship will also now include the client’s 30+ Non-Manufacturing facilities across the U.S.

“The objective of each of these long time clients is to continue to leverage pihms’ proven track record and expertise, and allow its management to have more time to focus their energy on customers and business growth. The pihms relationship with these clients is a great example of how the pihms suite of solutions can be configured and expanded to meet the growing needs of the client,” Kalnas said.

About pihms:
pihms, Inc. is a Software as a Service (SaaS) provider focusing on best practices for tracking, measuring and managing human capital. pihms’ unique (and patented) process takes employee health, safety, leave management, and case management information from disparate sources and delivers it to the right decision makers at the right time. The workflow ensures that best practices are used to remain compliant with all FML and OSHA regulations. pihms, Inc. is headquartered in Pittsburgh with offices in Atlanta and Glasgow, Scotland. For more information visit the pihms website at www.pihms.com.

Click here to see all recent news from this company

IRVING, TX–(Marketwire – September 14, 2010) – Boston-based Beth Israel Deaconess Medical Center, one of the East Coast’s most prestigious academic medical centers and a major teaching affiliate of Harvard Medical School, has joined VHA Inc., the national health care network. In joining VHA, BIDMC links with a large and growing network of hospitals and health systems across the country that work together to improve quality, increase efficiencies and control costs.

“Supply costs are the second biggest expense category in our budget. We’re seeking to aggressively manage costs as part of our commitment to provide the best health care possible in a responsible, cost-effective manner,” said Eric Buehrens, executive vice president and chief operating officer at BIDMC. “We are constantly looking to achieve and sustain supply chain excellence.” 

“VHA’s network includes some of the best health care organizations in the nation, so we’re excited to have Beth Israel Deaconess Medical Center join,” said Curt Nonomaque, VHA’s president and CEO. “We have a demonstrated track record of helping health care organizations drive clinical and operational improvements and connect with other members to create mutual benefits. We look forward to doing the same for Beth Israel Deaconess Medical Center.”

BIDMC began its search for a new health care group purchasing organization in 2009 as the organization considered ways to drive efficiency in response to toughening economic realities and the pending demands of health care reform, said Robert Cherry, vice president of Support Services. He noted that BIDMC spends about $300 million annually on supplies, but expects VHA membership will enable BIDMC to identify and achieve significant savings over the next 18 months on commodity products, pharmaceuticals, their top spend categories overall and endomechanical devices. 

About VHA

VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. Formed in 1977, through its 16 regional offices, VHA serves 1,400 hospitals and more than 30,000 non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 7th best place to work in health care in 2009.

ALEXANDRIA, VA–(Marketwire – September 14, 2010) –  Good food, good music, and good conversation — three key ingredients to many Hispanic/Latino family gatherings. But what is missing from many of those get-togethers is a life-saving conversation about the family’s medical history. This Hispanic Heritage Month (September 15-October 15), the American Diabetes Association is encouraging people to discuss any family history of diabetes, a conversation that could help stop diabetes before it starts.

Type 2 diabetes disproportionately affects Hispanics/Latinos. In fact, the rates of type 2 diabetes are almost double that of non-Hispanic whites. More than 10% of Hispanics/Latinos in the United States have been diagnosed with diabetes.

“It is particularly important for Hispanics/Latinos to know they are at higher risk for type 2 diabetes,” said Lorena Drago, RD, CDE, American Diabetes Association volunteer. “It is common for families to have multiple members with diabetes, but they never talk about it. These family discussions are necessary so everyone knows their risk, especially the younger generations.”

If current trends continue, 1 in 2 minorities born today will develop diabetes. Oftentimes type 2 diabetes is not diagnosed until one or more of its complications have begun to develop, including blindness, nerve damage or heart disease. Hispanics/Latinos are at higher risk for developing these complications.

The good news is type 2 diabetes can be prevented or delayed with healthy eating and exercising. “By exercising 150 minutes a week, such as 30 minutes 5 days a week, and losing 5 %-10% of your body weight, you could reduce your chances of developing type 2 diabetes by 58%,” said Drago. “By making changes gradually, instead of all at once, you can stop type 2 diabetes from developing or stop diabetes complications from occurring.”

The American Diabetes Association offers various family-friendly resources to help people successfully make lifestyle changes to reduce the risk of developing type 2 diabetes or diabetes complications.

• MyFoodAdvisor™ — Available in English and Spanish at www.diabetes.org/myfoodadvisor, this award-winning online tool provides nutrition information for people with diabetes, those at risk, and anyone who wants to lose weight. Users can track what they eat, find healthier alternatives and search recipes. The comprehensive database includes many culturally appropriate foods for Hispanics/Latinos.

  “MyFoodAdvisor can help you explore different types of foods. For example, eating one extra serving of fruits or vegetables a day is a small change you can make to get you and your family started towards a healthier meal plan,” commented Drago.

• Feria de Salud Por Tu Familia — Feria is the Association’s outdoor community event which captures the festive elements of a street fair but maintains the important aspects of choosing and managing a healthier lifestyle for the entire Hispanic/Latino family. This family event includes music, dancing, nutritional information, cooking demonstrations and a variety of product and service booths. Visit www.diabetes.org/feria for event listings in your area.

  “Feria can arm you with information to help stop diabetes and its complications in its tracks. The event provides you and your family with creative ways to become active, new ideas for healthy recipes, and greater awareness of what resources are available in the community,” said Drago.

• Stop Diabetes® — People from around the country are joining the Association’s movement to Stop Diabetes once and for all. By visiting www.stopdiabetes.com, calling 800-DIABETES, or texting* JOIN to 69866, you can find out how to become involved in the movement. There are opportunities for every member of the family to share, act, learn and give and help stop diabetes.

  “Whether you want to join the Stop Diabetes movement for yourself or a loved one, it is important that we stand up together against this disease and say the status quo is no longer acceptable. Too many people and their loved ones have suffered from diabetes’ terrible toll. Joining the movement is the first step to say enough is enough,” commented Drago.

  *Standard data and message rates apply.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>